Updating Practices in an Evolving IV Iron and Anemia Environment: Practical Solutions
ANNA 2007 Satellite Symposium
Welcome and Introduction


Andrea Easom, MA, MNSc, APN, BC, CNN-NP
Please make sure that all slide images load before starting the lecture

Flash Player
Either option should work well.
Option 1 Progressive video.
Option 2 Audio only (slower connections)
Option 3 Streaming Video/Audio: If your connection hangs, switch on-line to audio mode

Windows Media Player
See audiofaq.htm for proper setting of Tabs with Internet Explorer to make the talk scroll properly. Does NOT work properly with Firefox 2.0.
Option 1 Streaming Server
Option 2 For slow connections, right click on preload icon and choose "save target as". Play file from saved location.

MP3 (not synchronized) Player
Option 1 Streaming, Firewall-friendly
Option 2 Preload (2-5 mB)

Audio FAQ
For problems and suggestions, please click on this link
This satellite symposium is sponsored by an unrestricted educational grant from Watson Pharma, Inc. This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on April 25, 2007 at the American Nephrology Nurses' Association (ANNA) Annual Meeting in Dallas, TX.

This activity provides 1.25 contact hours.

The American Nephrology Nurses’ Association (ANNA) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a Provider approved by the California Board of Registered Nursing, provider number CEP 00910 for 1.25 contact hours.
Posting Date: November 15, 2007
CE Credit Eligible Through: November 15, 2009
CE Credit Hours/Completion Time: 1.25
Target Audiences: Nurses, nurse practitioners, and technicians.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.
 
SPEAKER DISCLOSURE STATEMENT and OFF-LABEL USE:
Ms. Easom is a Speakers Bureau member for Abbott, Amgen, and Watson Pharma, Inc.
(Always check the official drug label for FDA-approved indications.)

SPONSORSHIP / SUPPORT:
This ANNA Satellite symposium was developed in conjunction with Fallon Medica LLC, and the ANNA, and sponsored by an unrestricted educational grant from Watson Pharma, Inc.

ANNA and HDCN CE POLICY STATEMENTS:
The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.

00:00




Welcome
Good morning and welcome to the last day of this great National ANNA Meeting. I'm so happy to see so many of you that rose early and were ready to get up and go, and I want to welcome you.

00:20




Introduction
So with that aside, let's go ahead and start with the introduction. Your first speaker is moi (me), and my name is Andrea Easom, for those of you that don't know me. I'm an Instructor in the College of Medicine at the University of Arkansas for Medical Sciences. My major focus is to train nephrology fellows. I'm the key faculty for the dialysis rotation and for the chronic kidney disease clinics. So I have 8 fellows that I'm responsible for, but as you know that's not all nurses do. I also very openly precept nurses from our College of Nursing Program and work closely with the nurses in the dialysis unit in the renal clinics to manage our patient caseload.

As far as ANNA, I've been a Past National Chairperson of the Legislative Committee, a Past Chairman for the APN SIG, I now serve you all on the NNCC Credentialing Commission, and I sit on the NP Board Committee of that commission. I serve right now as the State Chapter President for the Arkansas Chapter, and that shows you that we really need more participating members in Arkansas. So we're working heavily to try to mentor people to be active in our chapters, and I'm sure a lot of you are doing the same thing, and I'm the State Legislative Director.

Believe me, if you are sitting in this audience, ANNA has a spot of service that you can fill. And if you're willing, you just make that known, and you'll be gladly involved in a short time in your local chapters. And if you have needs that your chapters are not meeting, please let them know that, too, because that's something that they are interested in addressing.

02:13




Program Objectives
These are the overall program objectives that are up there. I'm going to focus on the first one, which is to examine how facility staff can take a collaborative approach to updating anemia management practices. And as I talk, and as the other speakers talk, I really want you to think about the protocols that you have in your unit, and about individual patients that you have. And hopefully, things that we say will trigger you to go and look at those patients to see what is going on with them.

The next speaker is going to be Peter Juergensen, who is sitting here. He is a Physician's Assistant. His focus is Nephrology. He is with Nephrology Metabolism Associates and the Renal Research Institute. He also works with the Yale University College of Nursing and College of Medicine in Connecticut. So he plays a lot of roles, also.

And then, Dr. Richard Amerling. He has been on quite an adventure to get with us today. He got diverted last night to Houston and had to drive over. So many of you slept in a nice bed last night. He got to sleep in a nice limo coming over, and we're happy to have him. He is the director of Outpatient Dialysis and CRRT at Beth Israel Medical Center.

But what you need to know is, that the people who are up here on the panel today are the same kind of prescribers whom you have in your units. So you have protocols that you are mandated to follow, because if you have a protocol in your unit, then you have to follow it. That's just kind of how it is, unless you have prescriptive authority. But we're also not only nurses and employees of different facilities and different entities, but we're also patient advocates. So as your patients fall out of protocols then, as you assess them, it's very important to take that information to the prescribers in your units, to address those issues for those outliers. You don't just have to stop your ESA or stop your iron. You assess what's going on and bring your concerns to whomever the prescribers are, because they may not be as up on what's going on with that particular patient in that area that you have outlined and found in your own practice. So keep this in mind as we go on.

Peter is going to identify strategies for implementing a maintenance IV iron protocol and how to improve patient outcomes. And those come from some of his practice experience. And then Dr. Amerling is going to discuss some of the emerging information on ESA and IV iron therapies and its impact on treating patients with anemia, especially focusing on DRIVE I and DRIVE II.







TO GO TO NEXT TALK - by Ms. Easom - CLICK HERE
BACK TO
TOPIC INDEX :